SCHEMBL6550108

SCHEMBL6550108

O=C(O)c1ccc(Cl)c(S(=O)(=O)NCc2c(F)cccc2Cl)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 3/20 0.60
▸ L3MBTL1 Q9Y468 2/20 0.57
▸ TDP1 Q9NUW8 1/20 0.57
▸ PTK2B Q14289 2/20 0.51
▸ SMN1; SMN2 Q16637 2/20 0.51
▸ HTT P42858 1/20 0.48
▸ HSD17B10 Q99714 1/20 0.47
▸ LMNA P02545 3/20 0.47
▸ TP53 P04637 2/20 0.47
▸ MAPT P10636 2/20 0.47
▸ KMT2A Q03164 3/20 0.47
▸ MEN1 O00255 2/20 0.47
▸ SLC25A1 P53007 1/20 0.47
▸ KDM4E B2RXH2 1/20 0.46
▸ SLC12A2 P55011 1/20 0.45
▸ SLC12A5 Q9H2X9 1/20 0.45
▸ GPR55 Q9Y2T6 1/20 0.45
▸ PKM P14618 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6550216 0.81 POLB (0.62) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL11598628 0.80 POLB (0.65) POLBL3MBTL1TDP1PTK2BSMN1; SMN2
SCHEMBL18723228 0.80 POLB (0.75) POLBL3MBTL1TDP1HTTHSD17B10
SCHEMBL2877940 0.80 POLB (0.52) POLBL3MBTL1TDP1HTTLMNA
SCHEMBL11712963 0.75 POLB (0.61) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL13543501 0.75 POLB (0.57) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL6550219 0.74 POLB (0.60) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL9436722 0.73 POLB (0.58) POLBL3MBTL1TDP1SMN1; SMN2HTT
SCHEMBL11596502 0.73 AKR1C3 (0.62) POLBL3MBTL1TDP1HTTHSD17B10
SCHEMBL6550922 0.72 POLB (1.00) POLBL3MBTL1TDP1HTTLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1341754-B1 SUBSTITUTED ANTHRANILIC ACIDS AVENTIS PHARMA GMBH (DE) 2004-12-08 — — EP disclosed
US-6593352-B2 2-phenylalkylaminobenzoic acid containing substituted benzylsufamoyl group; useful for treating cardiovascular disorders, and for preserving or storing a transplant for surgery AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-07-15 — — US disclosed
US-20020123632-A1 Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2002-09-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020123632-A1 Substituted anthranilic acids, their use as a medicament or diagnostic, and medicament comprising them, and a pharmaceutical combination preparation containing a sodium/hydrogen exchange (NHE) blocker SLC10A1, SLC9A1, SLC9A2 POLB 2938/4885L3MBTL1 4881/4885TDP1 4130/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback